ArticleCancer medicine2026
Racial and Ethnic Disparities in Pharmacologic and Non-Pharmacologic Pain Management Among Older Cancer Survivors.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Racial and Ethnic Disparities in Pharmacologic and Non-Pharmacologic Pain Management Among Older Cancer Survivors.Cancer medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionPain is common among cancer survivors and often managed with medication; however, racial-ethnic disparities persist in pain treatment. Given inadequate data on pharmacologic and non-pharmacologic pain management among minoritized cancer survivors, we investigated these patterns using the SEER-Medicare claims linked database.
methodsAn incident cancer diagnosis cohort (≥ 66 years) was created from 2007 to 2016. The primary outcome was incidence of pain treatment (pharmacologic and non-pharmacologic) within 90 days post-diagnosis. Racial disparities were measured as adjusted incidence ratios for treatment using Poisson regression and adjusted differences in supply days and doses using linear regression, comparing non-Hispanic Black (nHB), Hispanic-Latino (LatinX), Asian/Pacific Islander (API), and Others to non-Hispanic White (nHW). Models were adjusted for demographic and clinical variables.
resultsAmong 300,048 survivors-nHW (72.9%), nHB (9.6%), LatinX (8.8%), API (7.3%), Others (1.4%)-nHB (aIR = 0.96, 95% CI, 0.95-0.98), API (aIR = 0.96, 95% CI, 0.95-0.98) and Others (aIR = 0.91, 95% CI, 0.87-0.94) used less pain treatment overall than nHW. Opioids (80% of treatments) were less frequently utilized by males of the Other race-ethnicity group (aIR = 0.75, 95% CI, 0.70-0.81), compared to nHW males. For non-opioids, nHB males (aIR: 0.84, 95% CI, 0.79-0.88) were less likely to use these therapies as compared to nHW males. Non-pharmacological treatments were less utilized by nHB (aIR = 0.65, 95% CI, 0.62-0.69) and LatinX survivors (aIR = 0.69, 95% CI, 0.65-0.73), as compared to nHWs. Minority survivors received lower opioid doses for longer durations, but higher non-opioid doses for shorter durations.
conclusionThere are considerable racial-ethnic disparities in the utilization of pharmacologic and non-pharmacologic pain treatments among cancer survivors. Future research should explore the drivers of these inequities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.